Evidence map›Paper›PMID 33116854›Full record

ArticleCancer management and research2020

Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia.

Marta Masternak, Bartosz Puła, Joanna Knap, Anna Waszczuk-Gajda, Joanna Drozd-Sokołowska, Kamil Wdowiak, Sebastian Grosicki, Izabela Kozłowska, Marta Kaźmierczak, Anna Łabędź and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Marta MasternakDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0001-5947-7610
Bartosz PułaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.ORCID 0000-0003-0116-5002
Joanna KnapDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0003-3157-8641
Anna Waszczuk-GajdaDepartment of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0001-5626-1750
Joanna Drozd-SokołowskaDepartment of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0002-4562-6264
Kamil WdowiakDepartment of Internal Medicine and Oncological Chemotherapy, Silesian Medical University, Katowice, Poland.ORCID 0000-0001-8176-4245
Sebastian GrosickiDepartment of Hematology and Cancer Prevention in Chorzow, Faculty of Health Sciences in Bytom, Silesian Medical University, Katowice, Poland.ORCID 0000-0003-2644-1050
Izabela KozłowskaDepartment of Hematology and Cancer Prevention, Municipal Hospital in Chorzów, Chorzów, Poland.ORCID 0000-0002-1476-9158
Marta KaźmierczakDepartment of Hematology and Cancer Prevention, Municipal Hospital in Chorzów, Chorzów, Poland.
Anna ŁabędźDepartment of Hematology, Rydrygier's Hospital in Cracow, Cracow, Poland.
Łukasz SzukalskiDepartment of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Toruń, Poland.
Kamil WiśniewskiDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.ORCID 0000-0003-4164-9343
Edyta SuboczDepartment of Hematology, Military Institute of Medicine, Warsaw, Poland; Clinical Department of Hematology, Independent Public Healthcare Centre of the Ministry of Internal Affairs and Administration with Warmia-Mazury Region's Oncology Centre in Olsztyn, Olsztyn, Poland.
Janusz HałkaClinical Department of Hematology, Independent Public Healthcare Centre of the Ministry of Internal Affairs and Administration with Warmia-Mazury Region's Oncology Centre in Olsztyn, Olsztyn, Poland.
Agnieszka SzymczykDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland; Hematology Department, St John's Cancer Center, Lublin, Poland.
Marek HusDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Krzysztof JamroziakDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland; Hematology Department, St John's Cancer Center, Lublin, Poland.
Medical University of Lublin · PLInstytut Hematologii i Transfuzjologi · PLMedical University of Silesia · PLMedical University of Warsaw · PLCracow University of Technology · PLNicolaus Copernicus University · PLWojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMean platelet volume (MPV) is a readily accessible and commonly tested hematological indicator. Recent studies revealed a significant impact of MPV on the course and prognosis of many diseases, including some types of cancer, as well as on the incidence of atrial fibrillation and bleeding. The study aimed to perform a retrospective analysis of MPV in terms of time to first treatment (TTFT) and to determine its prognostic value in the group of patients with chronic lymphocytic leukemia (CLL). Moreover, the study includes a retrospective analysis of platelet parameters in patients treated with ibrutinib concerning bleeding and atrial fibrillation. PATIENTS AND

methodsThe study included 523 patients with CLL, for 344 the most important cytogenetic aberrations were reported. The Mann-Whitney, Kruskal-Wallis, Kaplan-Meier, chi-squared, log‑rank tests and multivariate Cox proportional hazard regression model were used to analyze collected data.

resultsThe receiver operating characteristic curve analysis was performed to identify optimal cut-off value for MPV. The analysis of survival curves showed that in the group of patients with higher values of MPV TTFT was significantly longer than in the group with lower MPV (17.9 vs 36 months, p=0.0015, cut-off value for MPV= 10.4 fl). In multivariate Cox proportional hazard regression model low MPV, the presence of del11q and del13q provided independent prognostic value for TTFT (HR=0.69, 95%-CI, 0.5293 to 0.9081; p=0.0078; HR=1.76, 95%-CI, 1.3000 to 2.3882, p=0.0003, HR=0.74, 95%-Cl, 0.5674 to 0.9588, p=0.0229, respectively). In the group treated with ibrutinib, 59 patients had no significant correlation between MPV level and the incidence of therapy complications, although in the group of patients with low MPV there was a tendency for more frequent occurrence of atrial fibrillation (p=0.259).

conclusionLow MPV values are associated with unfavorable prognosis and might represent a novel, independent prognostic factor in CLL.

Indexed as

chronic lymphocytic leukemiaMPVTTFT

Identifiers

PMID33116854
PMCPMC7567945
OpenAlexW3092531239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.